Hannah C Slater1, Patrick G T Walker1, Teun Bousema2, Lucy C Okell1, Azra C Ghani1. 1. MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, Norfolk Place, United Kingdom. 2. Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, Netherlands Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, United Kingdom.
Abstract
BACKGROUND: Ivermectin (IVM), used alongside mass treatment strategies with an artemisinin combination therapy, has been suggested as a possible tool for reducing malaria transmission. Mosquitoes ingesting a bloodmeal containing IVM have increased mortality, reducing the probability that the parasite completes sporogony. METHODS: Human pharmacokinetic data and mortality data for mosquitoes taking bloodmeals containing IVM are used to quantify the mosquitocidal effect of IVM. These are incorporated into a transmission model to estimate the impact of IVM in combination with mass treatment strategies with artemether-lumefantrine on transmission metrics. RESULTS: Adding IVM increases the reductions in parasite prevalence achieved and delays the reemergence of parasites compared to mass treatment alone. This transmission effect is obtained through its effect on vector mortality. IVM effectiveness depends on coverage with the highest impact achieved if given to the whole population rather than only those with existing detectable parasites. Our results suggest that including IVM in a mass treatment strategy can reduce the time taken to interrupt transmission as well as help to achieve transmission interruption in transmission settings in which mass treatment strategies alone would be insufficient. CONCLUSIONS: Including IVM in mass treatment strategies could be a useful adjunct to reduce and interrupt malaria transmission.
BACKGROUND: Ivermectin (IVM), used alongside mass treatment strategies with an artemisinin combination therapy, has been suggested as a possible tool for reducing malaria transmission. Mosquitoes ingesting a bloodmeal containing IVM have increased mortality, reducing the probability that the parasite completes sporogony. METHODS: Human pharmacokinetic data and mortality data for mosquitoes taking bloodmeals containing IVM are used to quantify the mosquitocidal effect of IVM. These are incorporated into a transmission model to estimate the impact of IVM in combination with mass treatment strategies with artemether-lumefantrine on transmission metrics. RESULTS: Adding IVM increases the reductions in parasite prevalence achieved and delays the reemergence of parasites compared to mass treatment alone. This transmission effect is obtained through its effect on vector mortality. IVM effectiveness depends on coverage with the highest impact achieved if given to the whole population rather than only those with existing detectable parasites. Our results suggest that including IVM in a mass treatment strategy can reduce the time taken to interrupt transmission as well as help to achieve transmission interruption in transmission settings in which mass treatment strategies alone would be insufficient. CONCLUSIONS: Including IVM in mass treatment strategies could be a useful adjunct to reduce and interrupt malaria transmission.
Authors: Lais Pessanha de Carvalho; Thaisa Lucas Sandri; Edésio José Tenório de Melo; Rolf Fendel; Peter G Kremsner; Benjamin Mordmüller; Jana Held Journal: Antimicrob Agents Chemother Date: 2019-07-25 Impact factor: 5.191
Authors: Andrew M Bellinger; Mousa Jafari; Tyler M Grant; Shiyi Zhang; Hannah C Slater; Edward A Wenger; Stacy Mo; Young-Ah Lucy Lee; Hormoz Mazdiyasni; Lawrence Kogan; Ross Barman; Cody Cleveland; Lucas Booth; Taylor Bensel; Daniel Minahan; Haley M Hurowitz; Tammy Tai; Johanna Daily; Boris Nikolic; Lowell Wood; Philip A Eckhoff; Robert Langer; Giovanni Traverso Journal: Sci Transl Med Date: 2016-11-16 Impact factor: 17.956
Authors: Marie Miglianico; Maarten Eldering; Hannah Slater; Neil Ferguson; Pauline Ambrose; Rosemary S Lees; Karin M J Koolen; Katerina Pruzinova; Magdalena Jancarova; Petr Volf; Constantianus J M Koenraadt; Hans-Peter Duerr; Graham Trevitt; Baiyuan Yang; Arnab K Chatterjee; John Wisler; Angelika Sturm; Teun Bousema; Robert W Sauerwein; Peter G Schultz; Matthew S Tremblay; Koen J Dechering Journal: Proc Natl Acad Sci U S A Date: 2018-07-02 Impact factor: 11.205
Authors: Carlos Chaccour; Ángel Barrio; Ana Gloria Gil Royo; Diego Martinez Urbistondo; Hannah Slater; Felix Hammann; Jose Luis Del Pozo Journal: Malar J Date: 2015-03-05 Impact factor: 2.979
Authors: Carlos J Chaccour; N Regina Rabinovich; Hannah Slater; Sara E Canavati; Teun Bousema; Marcus Lacerda; Feiko Ter Kuile; Chris Drakeley; Quique Bassat; Brian D Foy; Kevin Kobylinski Journal: Malar J Date: 2015-06-11 Impact factor: 2.979
Authors: Hermann S Pooda; Jean-Baptiste Rayaisse; Domonbabele François de Sale Hien; Thierry Lefèvre; Serge R Yerbanga; Zakaria Bengaly; Roch K Dabiré; Adrien M G Belem; Issa Sidibé; Philippe Solano; Karine Mouline Journal: Malar J Date: 2015-12-10 Impact factor: 2.979